Ascentage Pharma Group International (NASDAQ:AAPG) Sees Unusually-High Trading Volume – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw an uptick in trading volume on Thursday . Approximately 5,773 shares traded hands during mid-day trading, a decline of 15% from the previous session’s volume of 6,823 shares.The stock last traded at $17.45 and had previously closed at $16.81.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. BTIG Research restated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research note on Friday, August 21st. Finally, B. Riley Financial started coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Trading Up 4.7%

The stock has a fifty day simple moving average of $18.21 and a 200 day simple moving average of $20.80. The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million during the quarter. As a group, analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

Several hedge funds have recently bought and sold shares of AAPG. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the third quarter valued at about $383,000. Hsbc Holdings PLC purchased a new stake in shares of Ascentage Pharma Group International in the second quarter worth about $391,000. Finally, UBS Group AG boosted its stake in Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after buying an additional 10,988 shares during the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.